While the market for electronic detailing in the U.S. has reached nearly a point of saturation at roughly half of all practicing physicians, the European market is still in an early stage of development and adoption. In fact, only 15% of European physicians have participated in an electronic detailing program today, a number that has remained statistically stagnant year over year. Traditionally, pharmaceutical companies had a limited array of sources available to them to communicate with physicians - the sales force, dinner meetings, conferences, and sponsorships. But today's European physician is media savvy and interested in receiving content from a wide variety of professional information and clinical news sources. Cybercitizen® Health Europe is a syndicated multi-client study and advisory service focused on key research topics and trends impacting the European consumer health marketplace. The study was fielded online among 4,302 European consumers from the United Kingdom, Germany, Spain, Italy, France, Belgium, Sweden, the Netherlands, Poland and Portugal. The survey instrument was presented in the native language of each individual country. 
Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented today at the 2007 Crohn's & Colitis Foundationâs 6th Annual Advances in the Inflammatory Bowel Diseases conference. 
Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, has launched its new intellectual property research and analysis solution, Thomson Innovation. 
The European Commission, the European Medicines Agency (EMEA) and the United States (US) Food and Drug Administration (FDA) have adopted a common application form for sponsors seeking orphan designation of medicines in the European Union (EU) and US. This initiative is aimed at simplifying the process of obtaining orphan status for medicines intended for rare diseases in both jurisdictions. 